Mithrl raised $20 million in a Series A to expand its AI platform for accelerating R&D through a biomedical “world model” and agentic tooling. The company said its next-generation system targets faster path-to-IND timelines for biotech teams while emphasizing validated biology and source-linked outputs to reduce drift from unverified claims.